Regeneron Presented Two-Year Results from (PHOTON) Trial of Aflibercept for Diabetic Macular Edema at ASRS 2023
Shots:
- The positive 2yr. results from the (PHOTON) trial evaluating aflibercept (8mg extended dosing intervals) vs Eylea. Aflibercept is being jointly developed by Regeneron & Bayer
- The trial met its 1EPs i.e., patients treated with aflibercept (8mg) achieved clinically equivalent vision gains over Eylea, mean no. of inj. administered for 12 & 16wk. aflibercept 8mg group were 9.5 & 7.8 vs 13.8 for the Eylea group through 2yr.
- Patients maintained ≥12 & ≥16wk. dosing intervals (89% vs 93%) & (84% vs 89%) through 1yr. while 44% met the criteria for ≥20wk. dosing intervals at 96wk. incl. 17% and 27% were eligible for 20 & 24wk. dosing intervals, respectively. The safety was similar to Eylea through 2yrs. and remained consistent with the known safety profile of Eylea from previous clinical trials
Ref: Globenewswire | Image: Regeneron
Related News:- Celltrion Seeks Marketing Authorization for CT-P42 (biosimilar, aflibercept) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
